Delivery tech remains challenging with gene therapies for brain disorders
Biotech executives discuss why developing gene therapies for central nervous system disorders remains difficult at a recent conference.
Biotech executives discuss why developing gene therapies for central nervous system disorders remains difficult at a recent conference.
What's Your Reaction?
